Dioseve Inc.
Development of Assisted Reproductive Technology Using Ovarian Cells Derived from iPS Cells
As of November, 2025
| City | Year of Establishment | Founder |
|---|---|---|
| Koto-ku, Tokyo | 2021 | Kazuma Kishida |
| Partner VC | Latest round of Fundraising | Valuation |
|---|---|---|
| Archtype Ventures | Series A | — |
- Contact Information: k-kishida＠dioseve.com
- Website: Dioseve Inc.
Program name
Deep-Tech Startups Support Program
Research theme
Development of Assisted Reproductive Technology Using Ovarian Cells Derived from iPS Cells
Business Plan
- Oocyte Culture Reagent Business Manufacture and sale of iPS cell-derived ovarian-like cells as an in vitro oocyte culture solution
- Infertility Treatment Service Business
Provision of infertility treatment services using oocytes created from the woman's own cells
Research Outline
This project involves introducing genes into established allogeneic iPS cells to generate ovarian cells, thereby providing an in vitro egg culture product as a new treatment option for reproductive medicine. This approach significantly improves the success rate of in vitro fertilization while simultaneously reducing the physical and psychological burden on women.
| Phase | Business Area/Field | Research Period | Research Grant Amount |
|---|---|---|---|
| STS | Healthcare | 2025-2026FY | — |
International collaborative technology demonstration
| Countries/Regions | Collaborative activity outline |
|---|---|
| United Kingdom | Through collaboration with the University of Manchester (UoM), we will receive research-grade human oocytes from the UK. |
Last Updated : April 21, 2026